It may not be much of a surprise that narcissistic CEOs of pharmaceutical companies will make bold choices, such as adopting radically new technology. That idea remains true, despite a lengthy correction to a paper that supports it.
The paper, “CEO Narcissism, Audience Engagement, and Organizational Adoption of Technological Discontinuities,” in Administrative Science Quarterly, found support for the following hypothesis:
Continue reading Paper on narcissistic CEOs earns big correction